Article Versions Notes

Vadivel K, Zaiss AK, Kumar Y, Fabian FM, Ismail AEA, Arbing MA, Buchholz WG, Velander WH, Bajaj SP. Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1. Journal of Clinical Medicine. 2020; 9(11):3684. https://doi.org/10.3390/jcm9113684

Vadivel, Kanagasabai, Anne K. Zaiss, Yogesh Kumar, Frank M. Fabian, Ayman E. A. Ismail, Mark A. Arbing, Wallace G. Buchholz, William H. Velander, and S. Paul Bajaj. 2020. "Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1" Journal of Clinical Medicine 9, no. 11: 3684. https://doi.org/10.3390/jcm9113684

Vadivel, K., Zaiss, A. K., Kumar, Y., Fabian, F. M., Ismail, A. E. A., Arbing, M. A., Buchholz, W. G., Velander, W. H., & Bajaj, S. P. (2020). Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1. Journal of Clinical Medicine, 9(11), 3684. https://doi.org/10.3390/jcm9113684